Highbridge Capital & Ayrmid offer $45M to buy bluebird bio, topping Carlyle/SK Capital's $29M bid, with additional payment ...
I believe Blue Bird shares could be near rock bottom, with potential support in the low $30s after a steep 40% selloff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback